Objective: Randomised controlled trials (RCTs) have given contradictory results about the efficacy and safety of ibandronate in treating metastatic bone disease (MBD) or multiple myeloma. This review meta-analysed the literature to gain a more comprehensive picture.
Design: Systematic review and meta-analysis of ibandronate compared with placebo or zoledronate.